194 related articles for article (PubMed ID: 10612710)
1. Synergistic interactions of endogenous opioids and cannabinoid systems.
Welch SP; Eads M
Brain Res; 1999 Nov; 848(1-2):183-90. PubMed ID: 10612710
[TBL] [Abstract][Full Text] [Related]
2. Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide.
Houser SJ; Eads M; Embrey JP; Welch SP
Brain Res; 2000 Feb; 857(1-2):337-42. PubMed ID: 10700588
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception.
Mason DJ; Lowe J; Welch SP
Eur J Pharmacol; 1999 Aug; 378(3):237-48. PubMed ID: 10493099
[TBL] [Abstract][Full Text] [Related]
4. Involvement of dynorphin B in the antinociceptive effects of the cannabinoid CP55,940 in the spinal cord.
Pugh G; Mason DJ; Combs V; Welch SP
J Pharmacol Exp Ther; 1997 May; 281(2):730-7. PubMed ID: 9152379
[TBL] [Abstract][Full Text] [Related]
5. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
6. Synergistic interactions between cannabinoid and opioid analgesics.
Cichewicz DL
Life Sci; 2004 Jan; 74(11):1317-24. PubMed ID: 14706563
[TBL] [Abstract][Full Text] [Related]
7. Opioids and cannabinoids interactions: involvement in pain management.
Desroches J; Beaulieu P
Curr Drug Targets; 2010 Apr; 11(4):462-73. PubMed ID: 20017728
[TBL] [Abstract][Full Text] [Related]
8. Interaction of the cannabinoid and opioid systems in the modulation of nociception.
Welch SP
Int Rev Psychiatry; 2009 Apr; 21(2):143-51. PubMed ID: 19367508
[TBL] [Abstract][Full Text] [Related]
9. Differential blockade of the antinociceptive effects of centrally administered cannabinoids by SR141716A.
Welch SP; Huffman JW; Lowe J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1301-8. PubMed ID: 9732392
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors.
Lake KD; Compton DR; Varga K; Martin BR; Kunos G
J Pharmacol Exp Ther; 1997 Jun; 281(3):1030-7. PubMed ID: 9190833
[TBL] [Abstract][Full Text] [Related]
11. The effects of endocannabinoid receptor agonist anandamide and antagonist rimonabant on opioid analgesia and tolerance in rats.
Altun A; Ozdemir E; Yildirim K; Gursoy S; Durmus N; Bagcivan I
Gen Physiol Biophys; 2015 Oct; 34(4):433-40. PubMed ID: 26374993
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
13. Synergistic and additive interactions of the cannabinoid agonist CP55,940 with mu opioid receptor and alpha2-adrenoceptor agonists in acute pain models in mice.
Tham SM; Angus JA; Tudor EM; Wright CE
Br J Pharmacol; 2005 Mar; 144(6):875-84. PubMed ID: 15778704
[TBL] [Abstract][Full Text] [Related]
14. Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase.
Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Dec; 600(1-3):50-8. PubMed ID: 18762181
[TBL] [Abstract][Full Text] [Related]
15. Decreased basal endogenous opioid levels in diabetic rodents: effects on morphine and delta-9-tetrahydrocannabinoid-induced antinociception.
Williams J; Haller VL; Stevens DL; Welch SP
Eur J Pharmacol; 2008 Apr; 584(1):78-86. PubMed ID: 18313663
[TBL] [Abstract][Full Text] [Related]
16. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
[TBL] [Abstract][Full Text] [Related]
17. Cannabinoids against pain. Efficacy and strategies to reduce psychoactivity: a clinical perspective.
Karst M; Wippermann S
Expert Opin Investig Drugs; 2009 Feb; 18(2):125-33. PubMed ID: 19236260
[TBL] [Abstract][Full Text] [Related]
18. Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.
O'Sullivan SE; Kendall DA; Randall MD
Eur J Pharmacol; 2005 Jan; 507(1-3):211-21. PubMed ID: 15659311
[TBL] [Abstract][Full Text] [Related]
19. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
20. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study.
Oviedo A; Glowa J; Herkenham M
Brain Res; 1993 Jul; 616(1-2):293-302. PubMed ID: 8395305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
